Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation). $10.0M Tranche Three draw under $125.0M Hercules Capital loan facility.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.03 · Creation of a Direct Financial Obligation
- $10.0M Tranche Three draw under $125.0M Hercules Capital loan facility
- Funding tied to achievement of clinical and financial milestones, signaling continued lender support
- Interest-only period and amortization date extended to June 1, 2028, improving near-term cash flexibility
- 60% minimum Qualified Cash covenant based on outstanding term-loan principal
- 1.0% tranche facility charge netted from proceeds, with 6.25% end-of-term charge remaining
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.